Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 119

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 119
---
 adversely affect our business, financial condition, or results of operations. In addition, our business depends on our ability to quickly and reliably deliver genetic test results to our customers. We typically receive samples from customers within days of shipment, or in some cases overnight, for genetic sequencing and data analysis at our laboratory facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather or natural disasters (including severe weather, fires or other natural events which may be exacerbated by climate change), pandemics or epidemics, terrorist acts or threats or for other reasons, could adversely affect specimen integrity and our ability to process specimens in a timely manner and otherwise service our customers, and ultimately materially and adversely affect our reputation and our business. In addition, our products incorporate complex computer software which may contain or result in errors or failures, especially when first introduced. In the course of conducting our business, we must adequately address quality issues associated with our products and services, including defects in our engineering and design processes, as well as defects in third -partycomponents included in our products. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after commercial shipment. Defects or errors in our test results may discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may affect our reputation substantially and could adversely affect our operating margins. Identifying the root cause of quality issues, particularly those sourced from third parties, may be difficult, which increases the time needed to address quality issues as they arise, and increases the risk that similar 34 problems could recur. As our products are designed to be used to perform complex genomic analysis, we expect that our customers will have an increased sensitivity to such defects. If we do not meet applicable regulatory or quality standards, our services may be subject to refunds, and, under certain circumstances, we may be required to notify applicable regulatory authorities about such refunds. If our products are subject to refunds or delivery holds, our reputation, business, financial condition, or results of operations could be adversely affected. We rely on a limited number of suppliers or, in some cases, sole suppliers for raw materials, key components or laboratory instruments, and an interruption in our ability to obtain such materials and services could adversely affect our business. We do not have manufacturing capabilities and do not plan to develop such capacity in the foreseeable future. Accordingly, we rely on a limited number of suppliers, or, in some cases, sole suppliers, including Illumina, Amoy Diagnostics Co.,